Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

According to CDC researchers, cases of tularemia in the U.S. increased by nearly 60% from 2011 to 2022 compared with the ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Expectant mothers will have access to free vaccines against respiratory syncytial virus (RSV) from next month under a major ...

“The availability of two different RSV protection methods in sufficient supply may have ... Several authors disclosed ties to pharmaceutical companies, including Pfizer, which manufactures the RSVpreF ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

The company lost more than $3 billion in market value after cutting its forecast for 2025 revenue from its COVID-19 and RSV ...

In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...